Atrophic rhinitis

Summary

Atrophic rhinitis (MONDO:0005659) is a disease and 4 clinical trials. Top therapeutic interventions include botulinum toxin type a. A subtype of rhinitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 4

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	atrophic rhinitis
Mondo ID	MONDO:0005659
EFO	EFO:0007159
MeSH	D012222
DOID	DOID:4731
SNOMED CT	69646003
UMLS	C0035459
MedGen	48450
Is cancer (heuristic)	no

Disease family

This is a subtype of rhinitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › otorhinolaryngologic disease › nasal disorder › nasal cavity disorder › rhinitis › atrophic rhinitis

Related subtypes (2): chronic rhinitis, allergic rhinitis

Subtypes (1): empty nose syndrome

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 4.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	3
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00732680	PHASE1/PHASE2	TERMINATED	Benefits of the Use of Botox in the Treatment of Empty Nose Syndrome Syndrome
NCT00832403	Not specified	SUSPENDED	Gore Tex Implants in the Treatment of Atrophic Rhinitis
NCT03112330	Not specified	COMPLETED	A Clinical Study to Evaluate the Safety and Efficacy of Platelet Rich Plasma Injection for Atrophic Rhinitis
NCT04717960	Not specified	UNKNOWN	Evaluation of Efficacy of Platelet Rich Plasma as Anew Modality for Treatment of Atrophic Rhinitis

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
BOTULINUM TOXIN TYPE A	4	1